Fas and Fas ligand: Expression and soluble circulating levels in cutaneous malignant melanoma

British Journal of Dermatology

Volumn 147, Issue 1, 2002, Pages 80-86

  Redondo, P ^a   Solano, T ^a   Vazquez B ^a   Bauza, A ^a   Idoate, M ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

ELISA; Fas; Fas ligand; Immunohistochemistry; Melanoma

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; LIGANDS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; SKIN NEOPLASMS; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036065905     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04745.x     Document Type: Article

References (37)

1. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
2. Apoptosis by death factor
3. Molecular cloning and expression of the Fas ligand: A novel member of the tumor necrosis factor family
4. Inhibition of death receptor signals by cellular FLIP
5. Regulation of the Fas lytic pathway in cloned CTL
6. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
7. Human lung carcinomas express Fas ligand
8. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95)
9. Fas-ligand-induced apoptosis as a mechanism of immune privilege
10. Immunohistochemical study on Fas and Fas ligand in skin wound healing
11. Fas ligand is expressed in normal skin and in some cutaneous malignancies
12. Fas ligand in human serum
13. Circulating soluble Fas ligand in patients with gastric carcinoma
14. Plasma soluble Fas ligand concentration: Decrease in elderly men and increase in patients with gastric carcinoma
15. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
16. Human melanoma cells do not express Fas (Apo-1/CD95) ligand
17. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors
18. Fas ligand expression in normal and neoplastic cells of melanocytic origin
19. Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis
20. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily in normal and neoplastic cells
21. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10
22. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines
23. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker
24. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma
25. Serum soluble Fas levels in ovarian cancer
26. Soluble Fas in serum from patients with renal cell carcinoma
27. Regulation of tumor necrosis factor-alpha processing by a metalloproteinase inhibitor
28. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies
29. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
30. Identification of soluble APO-1 in supernatant of human B and T-cell lines and increased serum levels in B- and T-cell leukemias
31. Circulating soluble Fas concentration in breast cancer patients
32. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma
33. Prognostic significance of soluble Fas in the serum of patients with bladder cancer
34. Soluble CD95 (Fas/APO-1) in malignant glioma: No implications for CD95-based immunotherapy?
35. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy
36. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apop-tosis, in advanced melanoma
37. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles